CD33 and neoplasm: Indeed, the targeting of myeloid-lineage associated antigens such as CD33 and CD123 has been impeded by their expression in other tissues (CD33 in liver, CD123 in endothelial cells [7,8]), which raises issues of on-target off-tumor toxicity.